The latest report by IMARC, titled “Telmisartan Market Report by Indication (Hypertension, Cardiovascular Risk Reduction), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), and Region 2024-2032”, finds that the global telmisartan market size reached US$ 3.7 Billion in 2023. Telmisartan refers to an angiotensin receptor blocker (ARB) that works by blocking a chemical in the human body that tightens blood vessels. It is also primarily used for the treatment of hypertension and cardiovascular risk reduction. It is used alone as well as in combination with several other agents, including amlodipine and hydrochlorothiazide. Nowadays, it is generally available in the form of tablets and oral oil suspension variants and is dispensed with other medications to improve its efficacy. It also helps in relaxing the blood vessels and promoting kidney function. In recent years, telmisartan has gained traction with the rising number of individuals diagnosed with various chronic illnesses.
Global Telmisartan Market Trends:
One of the primary factors driving the market is the significant growth in the pharmaceutical industry. Additionally, the increasing incidences of diabetes, high blood pressure, and numerous kidney-related disorders are creating a positive market outlook. Other than this, telmisartan assists in modifying genes for insulin sensitization, regulating glucose and lipid metabolism, and managing chronic diabetic kidney disease and other disorders. This, coupled with the increasing marketing approvals for generic versions of telmisartan, is propelling the market growth. Besides this, the rising research on telmisartan drugs in emerging nations is escalating the product demand. Furthermore, extensive investment in research and development (R&D) activities by key players to advance telmisartan medications for the treatment of diabetic nephropathy is creating for a favorable market outlook. Other growth-inducing factors include improvements in healthcare infrastructure, rising geriatric population, and increasing number of individuals leading sedentary lifestyles. Looking forward, IMARC Group expects the market value to reach US$ 4.8 Billion by 2032, expanding at a CAGR of 2.7% during the forecast period (2024-2032).
Market Summary:
- Based on the indication, the market has been bifurcated into hypertension and cardiovascular risk reduction.
- On the basis of the distribution channel, the market has been divided into hospital pharmacies, drug stores and retail pharmacies, and online stores.
- Region-wise, the market has been classified into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
- The competitive landscape of the market has also been analyzed, with some of the key players being Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH, Cipla Limited, Hikma Pharmaceuticals pls, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.), and Torrent Pharmaceuticals Ltd.
Report Scope:
Report Features |
Details |
Base Year of the Analysis |
2023 |
Historical Period |
2018-2023 |
Forecast Period |
2024-2032 |
Units |
US$ Billion |
Segment Coverage |
Indication, Distribution Channel, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH , Cipla Limited, Hikma Pharmaceuticals plc, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.) and Torrent Pharmaceuticals Ltd. |
Report Price and Purchase Option |
Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899 |
Customization Scope |
10% Free Customization |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us
IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter : @imarcglobal